In Vitro and In Vivo Activities of Novel Fluoroquinolones Alone and in Combination with Clarithromycin against Clinically Isolated Mycobacterium avium Complex Strains in Japan
Open Access
- 1 November 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (11) , 4071-4076
- https://doi.org/10.1128/aac.00410-07
Abstract
The recommended treatments for Mycobacterium avium complex (MAC) infectious disease are combination regimens of clarithromycin (CLR) or azithromycin with ethambutol and rifamycin. However, these chemotherapy regimens are sometimes unsuccessful. Recently developed antimicrobial agents, such as newer fluoroquinolones (FQs) containing C-8 methoxy quinolone (moxifloxacin [MXF] and gatifloxacin [GAT]), are expected to be novel antimycobacterial agents. Here, we evaluated the in vitro and in vivo antimycobacterial activities of three FQs (MXF, GAT, and levofloxacin) and CLR against clinically isolated MAC strains. Subsequently, the in vitro and in vivo synergic activities of FQ-CLR combinations against MAC strains were investigated. CLR and the individual FQs alone showed promising activity against MAC strains in vitro, and the bacterial counts in organs (lungs, liver, and spleen) of MAC-infected mice treated with single agents were significantly reduced compared to control mice. CLR showed the best anti-MAC effect in vivo. When the three FQs were individually combined with CLR in vitro, mild antagonism was observed for 53 to 57% of the tested isolates. Moreover, mice were infected with MAC strains showing mild antagonism for FQ-CLR combinations in vitro, and the anti-MAC effects of the FQ-CLR combinations were evaluated by counting the viable bacteria in their organs and by histopathological examination after 28 days of treatment. Several FQ-CLR combinations exhibited bacterial counts in organs significantly higher than those in mice treated with CLR alone. Our results indicate that the activity of CLR is occasionally attenuated by combination with an FQ both in vitro and in vivo and that this effect seems to be MAC strain dependent. Careful combination chemotherapy using these agents against MAC infectious disease may be required.Keywords
This publication has 20 references indexed in Scilit:
- Synergism between β-Lactams and Glycopeptides against VanA-Type Methicillin-Resistant Staphylococcus aureus and Heterologous Expression of the vanA OperonAntimicrobial Agents and Chemotherapy, 2006
- Combined Effects of Panipenem and Aminoglycosides on Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in vitroChemotherapy, 2005
- Mycobacterium avium complex Pulmonary Disease in Patients Without HIV InfectionChest, 2004
- In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteriaInternational Journal of Antimicrobial Agents, 2003
- In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosisInternational Journal of Antimicrobial Agents, 2002
- In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2002
- Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium aviumAntimicrobial Agents and Chemotherapy, 2001
- Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 miceAntimicrobial Agents and Chemotherapy, 1995
- Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige miceAntimicrobial Agents and Chemotherapy, 1994
- Mycobacteria and the new quinolonesAntimicrobial Agents and Chemotherapy, 1989